{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:38:58Z","timestamp":1790667538295,"version":"4.1.0"},"reference-count":54,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K22771"],"award-info":[{"award-number":["20K22771"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22fk0210075"],"award-info":[{"award-number":["JP22fk0210075"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20K22771"],"award-info":[{"award-number":["20K22771"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22fk0210075"],"award-info":[{"award-number":["JP22fk0210075"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis E virus (HEV) is increasingly recognized as the leading cause of acute hepatitis. Although HEV infections are mostly self-limiting, a chronic course can develop especially in those with immunocompromised state. Ribavirin is currently used to treat such patients. According to various reports on chronic HEV infections, a sustained virological response (SVR) was achieved in approximately 80% of patients receiving ribavirin monotherapy. To increase the SVR rate, drug combination might be a viable strategy, which we attempted in the current study. Ritonavir was identified in our previous drug screening while searching for candidate novel anti-HEV drugs. It demonstrated potent inhibition of HEV growth in cultured cells. In the present study, ritonavir blocked HEV internalization as shown through time-of-addition and immunofluorescence assays. Its combination with ribavirin significantly increased the efficiency of inhibiting HEV growth compared to that shown by ribavirin monotherapy, even in PLC\/PRF\/5 cells with robust HEV production, and resulted in viral clearance. Similar efficiency was seen for HEV genotypes 3 and 4, the main causes of chronic infection. The present findings provide insight concerning the advantage of combination therapy using drugs blocking different steps in the HEV life cycle (internalization and RNA replication) as a potential novel treatment strategy for chronic hepatitis E.<\/jats:p>","DOI":"10.3390\/v14112440","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T04:15:23Z","timestamp":1667535323000},"page":"2440","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ritonavir Blocks Hepatitis E Virus Internalization and Clears Hepatitis E Virus In Vitro with Ribavirin"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7401-979X","authenticated-orcid":false,"given":"Putu Prathiwi","family":"Primadharsini","sequence":"first","affiliation":[{"name":"Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-713X","authenticated-orcid":false,"given":"Shigeo","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Murata","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-0964","authenticated-orcid":false,"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Tochigi 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"001778","DOI":"10.1099\/jgv.0.001778","article-title":"ICTV Virus Taxonomy Profile: Hepeviridae 2022","volume":"103","author":"Purdy","year":"2022","journal-title":"J. Gen. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0042-6822(91)90760-9","article-title":"Hepatitis E virus (HEV): Molecular cloning and sequencing of the full-length viral genome","volume":"185","author":"Tam","year":"1991","journal-title":"Virology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1128\/JVI.73.10.8848-8850.1999","article-title":"Evidence that the genomic RNA of hepatitis E virus is capped","volume":"73","author":"Meng","year":"1999","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1073\/pnas.89.17.8259","article-title":"Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: Delineation of an additional group of positive-strand RNA plant and animal viruses","volume":"89","author":"Koonin","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jceh.2013.05.001","article-title":"Hepatitis E: Molecular virology and pathogenesis","volume":"3","author":"Panda","year":"2013","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1099\/vir.0.010561-0","article-title":"ORF3 protein of hepatitis E virus is essential for virion release from infected cells","volume":"90","author":"Yamada","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1128\/JVI.00593-10","article-title":"Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif","volume":"84","author":"Emerson","year":"2010","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1099\/vir.0.025791-0","article-title":"A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells","volume":"92","author":"Nagashima","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1073\/pnas.1614955114","article-title":"Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles","volume":"114","author":"Ding","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00705-008-0179-6","article-title":"Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus (HEV) can capture HEV particles in culture supernatant and serum but not those in feces","volume":"153","author":"Takahashi","year":"2008","journal-title":"Arch. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1128\/JCM.02002-09","article-title":"Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: Characterization of HEV virions in blood circulation","volume":"48","author":"Takahashi","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/JVI.02804-15","article-title":"Distinct entry mechanisms for nonenveloped and quasi-enveloped Hepatitis E viruses","volume":"90","author":"Yin","year":"2016","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/JVI.00822-17","article-title":"Characterization of the quasi-enveloped hepatitis E virus particles released by the cellular exosomal pathway","volume":"91","author":"Nagashima","year":"2017","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrgastro.2017.150","article-title":"Hepatitis E virus: Advances and challenges","volume":"15","author":"Nimgaonkar","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","article-title":"Hepatitis E virus and chronic hepatitis in organ-transplant recipients","volume":"358","author":"Kamar","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1537-2995.2004.03300.x","article-title":"Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan","volume":"44","author":"Matsubayashi","year":"2004","journal-title":"Transfusion"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/jmv.20215","article-title":"Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: Evidence for infection with a genotype 3 HEV by blood transfusion","volume":"74","author":"Mitsui","year":"2004","journal-title":"J. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-3148.2006.00652.x","article-title":"Transfusion-transmitted hepatitis E in a \u2018nonhyperendemic\u2019 country","volume":"16","author":"Boxall","year":"2006","journal-title":"Transfus. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/trf.13994","article-title":"Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression","volume":"57","author":"Satake","year":"2017","journal-title":"Transfusion"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1929","DOI":"10.1002\/rmv.1929","article-title":"Hepatitis E and pregnancy: Current state","volume":"27","year":"2017","journal-title":"Rev. Med. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1440-1746.2007.04913.x","article-title":"Hepatitis E virus infection and fulminant hepatic failure during pregnancy","volume":"22","author":"Jilani","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_22","unstructured":"World Health Organization (2022, September 12). Hepatitis E. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-e."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.3748\/wjg.v22.i31.7030","article-title":"Hepatitis E: Discovery, global impact, control and cure","volume":"22","author":"Khuroo","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1101\/cshperspect.a032144","article-title":"Transmission and epidemiology of hepatitis E virus genotype 3 and 4 infections","volume":"8","author":"Dalton","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tmrv.2019.06.001","article-title":"Transfusion-transmitted hepatitis E virus infection in France","volume":"33","author":"Gallian","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2022.05.006","article-title":"Chronic hepatitis E: Advancing research and patient care","volume":"77","author":"Ma","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2018). EASL clinical practice guidelines on hepatitis E virus infection. J. Hepatol., 68, 1256\u20131271.","DOI":"10.1016\/j.jhep.2018.03.005"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/cid\/ciz953","article-title":"Ribavirin for hepatitis E virus infection after organ transplantation: A large European retrospective multicenter study","volume":"71","author":"Kamar","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/jvh.13456","article-title":"Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis","volume":"28","author":"Gorris","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0190621","DOI":"10.1128\/jvi.01906-21","article-title":"Development of recombinant infectious hepatitis E virus harboring the nanoKAZ gene and its application in drug screening","volume":"96","author":"Primadharsini","year":"2022","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1099\/vir.0.82535-0","article-title":"Development and evaluation of an efficient cell-culture system for hepatitis E virus","volume":"88","author":"Tanaka","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.virusres.2008.06.005","article-title":"Mutational events during the primary propagation and consecutive passages of hepatitis E virus strain JE03-1760F in cell culture","volume":"137","author":"Lorenzo","year":"2008","journal-title":"Virus Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/JCM.00629-09","article-title":"Development and characterization of a genotype 4 hepatitis E virus cell culture system using a HE-JF5\/15F strain recovered from a fulminant hepatitis patient","volume":"47","author":"Tanaka","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.virusres.2011.01.015","article-title":"Hepatitis E virus cell culture models","volume":"161","author":"Okamoto","year":"2011","journal-title":"Virus Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00705-008-0045-6","article-title":"Production of monoclonal antibodies against hepatitis E virus capsid protein and evaluation of their neutralizing activity in a cell culture system","volume":"153","author":"Takahashi","year":"2008","journal-title":"Arch. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1099\/vir.0.007559-0","article-title":"Construction of an infectious cDNA clone of hepatitis E virus strain JE03-1760F that can propagate efficiently in cultured cells","volume":"90","author":"Yamada","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: Visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1099\/vir.0.82808-0","article-title":"Characterization of Junin arenavirus cell entry","volume":"88","author":"Martinez","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/lt.20157","article-title":"Outcomes of acute rejection after interferon therapy in liver transplant recipients","volume":"10","author":"Saab","year":"2004","journal-title":"Liver Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/TCRM.S3285","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: A review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.572905","article-title":"Ritonavir-boosted protease inhibitors in HIV therapy","volume":"43","author":"Hull","year":"2011","journal-title":"Ann. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): A randomised, open-label trial","volume":"385","author":"Hezode","year":"2015","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/j.gastro.2015.07.001","article-title":"Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis","volume":"149","author":"Lawitz","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s40265-016-0612-1","article-title":"Ombitasvir\/paritaprevir\/ritonavir: A review in chronic HCV genotype 4 infection","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wong, C.K.H., Au, I.C.H., Lau, K.T.K., Lau, E.H.Y., Cowling, B.J., and Leung, G.M. (Lancet Infect. Dis., 2022). Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: A retrospective cohort study, Lancet Infect. Dis., Online ahead of print.","DOI":"10.1016\/S1473-3099(22)00507-2"},{"key":"ref_47","unstructured":"Panel on Treatment of HIV Drug Pregnancy and Prevention of Perinatal Transmission (2022, September 01). Recommendations for Use of Antiretroviral Drugs in Transmission in the United States, Available online: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/Perinatal_GL.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/gutjnl-2013-306155","article-title":"Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C","volume":"64","author":"Xiao","year":"2015","journal-title":"Gut"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1073\/pnas.1010693107","article-title":"Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir","volume":"107","author":"Sevrioukova","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","unstructured":"Food and Drug Administration (2022, September 01). Rebetol: Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020903s052,021546s008lbl.pdf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMc0903778","article-title":"Persistent carriage of hepatitis E virus in patients with HIV infection","volume":"361","author":"Dalton","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7326\/0003-4819-155-7-201110040-00017","article-title":"Treatment of chronic hepatitis E in a patient with HIV infection","volume":"155","author":"Dalton","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/liv.15076","article-title":"Maternal and fetal outcomes of pregnancies complicated by acute hepatitis E and the impact of HIV status: A cross-sectional study in Namibia","volume":"42","author":"Heemelaar","year":"2022","journal-title":"Liver Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/liv.15168","article-title":"Probing the direct effects of antiretroviral drugs on hepatitis E virus replication in cell culture models","volume":"42","author":"Li","year":"2022","journal-title":"Liver Int."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2440\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:09:59Z","timestamp":1760144999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["v14112440"],"URL":"https:\/\/doi.org\/10.3390\/v14112440","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}